Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb 27, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	351	427	415	234	106	395
Market Cap Growth	-23.78%	3.06%	77.46%	120.08%	-73.16%	-2.30%
Enterprise Value	360	460	484	301	121	363
Last Close Price	1.31	1.61	1.90	1.24	0.58	2.26
Forward PE	34.16	82.56	-	-	-	-
PS Ratio	1.49	1.81	2.59	1.20	0.36	1.87
PB Ratio	10.66	13.10	-8.43	-7.64	20.30	5.34
P/FCF Ratio	5.86	7.13	-	-	-	-
P/OCF Ratio	5.16	6.28	-	-	-	-
EV/Sales Ratio	1.52	1.95	3.02	1.55	0.41	1.71
EV/EBITDA Ratio	14.52	18.56	-	-	39.44	-
EV/EBIT Ratio	15.30	19.57	-	-	-	-
EV/FCF Ratio	6.00	7.68	-	-	-	-
Debt / Equity Ratio	5.94	5.94	-3.84	-4.72	30.07	2.56
Debt / EBITDA Ratio	7.82	7.82	-	-	18.82	-
Debt / FCF Ratio	3.23	3.23	-	-	-	-
Net Debt / Equity Ratio	0.27	0.27	-2.78	-3.31	12.77	0.53
Net Debt / EBITDA Ratio	0.35	0.35	-15.73	-14.76	21.86	-0.21
Net Debt / FCF Ratio	0.15	0.15	-3.36	-4.33	-0.91	-0.15
Asset Turnover	0.79	0.79	0.69	0.65	0.66	0.36
Inventory Turnover	2.69	2.69	1.64	2.13	0.77	1.67
Quick Ratio	1.42	1.42	1.07	0.82	1.01	0.79
Current Ratio	1.55	1.55	1.41	1.18	1.43	1.04
Return on Equity (ROE)	-	-	-	-	-237.83%	-175.37%
Return on Assets (ROA)	4.92%	4.92%	-12.49%	-9.30%	-4.89%	-24.27%
Return on Capital Employed (ROCE)	11.00%	11.00%	-33.10%	-31.40%	-15.30%	-84.90%
Earnings Yield	-1.52%	-1.25%	-16.74%	-22.23%	-88.77%	-71.32%
FCF Yield	17.07%	14.02%	-9.82%	-10.01%	-69.03%	-63.99%
Buyback Yield / Dilution	-21.91%	-21.91%	-12.53%	-2.56%	-10.14%	-19.85%

Updated Feb 26, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q